Lead: Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Lead: Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine
-
ナレーター：
-
著者：
このコンテンツについて
Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine
JAMA Network
This industry-sponsored, multicenter, open-label randomized clinical trial with 729 participants, assessed if rapid induction (RI) for initiating extended-release buprenorphine is as safe and effective as standard induction (SI) in individuals who inject opioids or use fentanyl. RI was well tolerated and had higher retention than SI at extended-release buprenorphine injection 2 overall and in fentanyl positive participants. Administering the second extended-release buprenorphine injection 1 week after the first was well tolerated in both the RI arm and SI arm. These findings suggest support RI for extended-release buprenorphine induction in high-risk patients and demonstrate the feasibility of administering the first 2 doses at least 1 week apart.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM